TMS Co (TSE:4891) Debt-to-EBITDA : N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4891 TMS Co Ltd TSE:4891
33 GF Score
Price 円109.00
! 1 Warning Sign
View Full Analysis

What is TMS Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

TMS Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was 円0.00 Mil. TMS Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was 円0.00 Mil. TMS Co's annualized EBITDA for the quarter that ended in Dec. 2025 was 円0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for TMS Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4891's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.29
* Ranked among companies with meaningful Debt-to-EBITDA only.

TMS Co  (TSE:4891) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

TMS Co Debt-to-EBITDA Related Terms

TMS Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for TMS Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMS Co Debt-to-EBITDA Chart

TMS Co Annual Data
Trend Feb21 Feb22 Feb23 Feb24 Feb25
Debt-to-EBITDA
0.00 0.00 0.00 0.00 0.00

TMS Co Quarterly Data
Feb21 Feb22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Feb25 May25 Aug25 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 N/A 0.00 0.00 N/A

TSE:4891 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, TMS Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TMS Co Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TMS Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TMS Co's Debt-to-EBITDA falls into.


TSE:4891
33GF Score
TMS Co Ltd TSE:4891
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

TMS Co's Debt-to-EBITDA for the fiscal year that ended in Feb. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -904.082
=0.00

TMS Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
33GF Score

Get the complete analysis for TSE:4891

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円109.00
Price